Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: XXXX medoxomil compared with @entity9886 , @entity917 , and @entity7056 .

@entity917 @entity1 @entity64 @entity101 @entity301 @entity7056 @entity15632 @entity9886 @entity9885 @entity583 @entity65
OBJECTIVE: To compare the cost effectiveness of the angiotensin II receptor blockers (ARBs) @entity15632 , @entity9886 , @entity917 and @entity7056 for the treatment of @entity101 , from the perspective of a US managed care setting. METHODS: The evaluation was based on a recently completed, prospective, randomised, double-blind clinical trial comparing the antihypertensive efficacy of these agents. Differences in diastolic blood pressure reductions among the comparative agents were used to estimate reductions in the annualised risk of cardiovascular (CV) and cerebrovascular events using the Framingham model. These annualised risks were translated into reductions in healthcare expenditures associated with treating CV events covered by managed care in the US. Data sources included: the recently published clinical trial of ARB antihypertensive efficacy, the Framingham Heart Study and a managed care database. Actual reimbursed amounts were used. RESULTS: Based on antihypertensive efficacy data versus @entity7056 , the use of @entity9885 medoxomil is expected to reduce the number of new cases of @entity65 , resulting in a first-year reduction in cost in a cohort of 100,000 @entity1 of 906,000 US dollars. Similarly, a reduction in new cases of @entity301 ( @entity301 ) resulted in a cost reduction of 701,000 US dollars; a cost reduction of 196,000 US dollars for fewer @entity583 ( @entity583 ); and a cost reduction of 28,000 US dollars for fewer @entity64 . Over 5 years, these estimates increase to 5,410,000 US dollars for fewer cases of @entity65 ; 3,975,000 US dollars for fewer cases of @entity301 ; 1,430,000 US dollars for fewer @entity583 ; and 497,000 US dollars for fewer @entity64 . Compared with @entity917 , the use of @entity9885 medoxomil is estimated to reduce by 3,397,000 US dollars the expected cost of treating a cohort of 100 000 @entity1 in the first year for fewer cases of @entity65 ; by 2,426,000 US dollars for fewer cases of @entity301 ; by 565,000 US dollars for fewer @entity583 ; and by 124,000 US dollars for fewer @entity64 . Over 5 years, these estimates increase to 16,231,000 US dollars for @entity65 ; 11,955,000 US dollars for @entity301 ; 4,505,000 US dollars for @entity583 ; and 1,741,000 dollars for @entity64 . Compared with @entity9886 , the estimated reduction in first-year cost is 2,969,000 US dollars for @entity65 for the cohort of 100,000 @entity1 ; 2,163,000 US dollars for @entity301 ; 732,000 US dollars for @entity583 ; and 124,000 US dollars for @entity64 . Over 5 years, these estimates increase to 15,149,000 US dollars for @entity65 ; 11,107,000 US dollars for @entity301 ; 4,057,000 US dollars for @entity583 ; and 1,437,000 dollars for @entity64 . CONCLUSION: Based on comparative antihypertensive efficacy data, treatment of @entity101 @entity1 with @entity9885 medoxomil instead of the other leading ARBs has the potential to reduce overall cost of medical care in a US managed care setting.
